Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CHOP Commits $50 Million To Gene Therapy Spin-Out Spark Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

Non-profit hospital spins out its first start-up, which will house one program to address a heritable form of blindness, another to treat hemophilia B.

You may also be interested in...



Cellular And Gene Therapy Trials Should Target Children First, FDA Advisors Say

Advisory committee members argued that children should be tested before adults in many situations where cellular or gene therapy is being considered.

Third Rock Takes On Parkinson's, Gene Therapy's Next Frontier

As gene therapy moves closer toward becoming an established therapeutic mode, developers have focused mainly on ophthalmology and monogenic rare diseases, but improvements in vector technology are pointing the field toward targets in the central nervous system. The latest entrant is Voyager Therapeutics Inc., which launched in February with a $45 million Series A commitment from Third Rock Ventures and a lead program in Parkinson's disease.

Start-Up Quarterly Statistics, Q4 2013

Life science start-ups raised $1.18 billion in the final quarter of 2013, more than twice the $559.4 million they garnered in the previous quarter, and the most lucrative quarter reported for the group in the history of this START-UP column.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS074926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel